BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

What's New in Pompe Disease?

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Wednesday, February 9, 2022
Sponsor Information: 

This Industry Update Webinar is sponsored by Sanofi Genzyme. This program is not sponsored, endorsed, or accredited by MDA.

Faculty

Dr. Shafeeq S. Ladha
Director of the Gregory W. Fulton ALS and Neuromuscular Disorders Center
Barrow Neurological Institute: Department of Neurology
Activity Overview: 

This Industry Update Webinar for clinicians is presented by Sanofi Genzyme and features information for clinicians on Pompe. Originally held on November 4, 2021 and updated on February 9, 2022 -- in a 30-minute webinar, Sanofi Genzyme presented "What's New in Pompe Disease." This webinar discussed updates in the Pompe disease landscape. The featured presenter of this Industry Update Webinar was Dr. Shafeeq S. Ladha, the Ira A. and Mary Lou Fulton Chair in Motor Neuron Diseases and Director of the Gregory W. Fulton ALS and Neuromuscular Disorders Center at Barrow Neurological Institute: Department of Neurology.